Assignee
NXERA PHARMA UK LTD
GB·15 granted patents·8 pending applications·0 citations·filing 2019–2025
Top patents by PatentIndex Score
23 records- 0185US12415795B24-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulatorsNXERA PHARMA UK LTD·Filed 2023·Granted Sep 16, 2025·0 cites·10 claims
- 0277US12202843B2Muscarinic receptor agonistsNXERA PHARMA UK LTD·Filed 2021·Granted Jan 21, 2025·0 cites·18 claims
- 0376US2025136616A1Cgrp antagonist compoundsNXERA PHARMA UK LTD·Filed 2024·Application pending·0 cites
- 0474US12054472B21,2,4-triazine-4-amine derivativesNXERA PHARMA UK LTD·Filed 2021·Granted Aug 6, 2024·0 cites·3 claims
- 0572US12178813B2CGRP receptor antagonistsNXERA PHARMA UK LTD·Filed 2020·Granted Dec 31, 2024·0 cites·22 claims
- 0670US12291512B2Oxime compounds as agonists of the muscarinic M1 and/or M4 receptorNXERA PHARMA UK LTD·Filed 2021·Granted May 6, 2025·0 cites·9 claims
- 0767US2026015314A1Prostaglandin ep4 receptor antagonist compoundsNXERA PHARMA UK LTD·Filed 2025·Application pending·0 cites
- 0866US12234227B2Pyrazole derivatives as H4 antagonist compoundsNXERA PHARMA UK LTD·Filed 2019·Granted Feb 25, 2025·0 cites·17 claims
- 0966US2026085056A1Ox1 receptor antagonistsNXERA PHARMA UK LTD·Filed 2025·Application pending·0 cites
- 1065US12331029B2Orexin 1 receptor antagonistsNXERA PHARMA UK LTD·Filed 2019·Granted Jun 17, 2025·0 cites·17 claims
- 1164US12227521B2CGRP antagonist compoundsNXERA PHARMA UK LTD·Filed 2020·Granted Feb 18, 2025·0 cites·31 claims
- 1263US2025368709A1Glp-1 receptor antagonistsNXERA PHARMA UK LTD·Filed 2025·Application pending·0 cites
- 1361US12391641B2Prostaglandin EP4 receptor antagonist compoundsNXERA PHARMA UK LTD·Filed 2020·Granted Aug 19, 2025·0 cites·27 claims
- 1461US2024376070A1Gpr52 modulator compoundsNXERA PHARMA UK LTD·Filed 2022·Application pending·0 cites
- 1560US2026042745A1Pyrrolidine-2-carboxamide derivatives as prostaglandin e2 receptor 4 (ep4) agonists for the treatment of gastrointestinal and pulmonary diseasesNXERA PHARMA UK LTD·Filed 2023·Application pending·0 cites
- 1659US12215099B2Quinolinone and benzoxazine derivatives as muscarinic M1 and/or M4 receptor agonistsNXERA PHARMA UK LTD·Filed 2019·Granted Feb 4, 2025·0 cites·11 claims
- 1755US2025340531A1Crystalline forms and salts of a muscarinic receptor agonistNXERA PHARMA UK LTD·Filed 2023·Application pending·0 cites
- 1854US2025313621A1Anti-par2 antibodiesNXERA PHARMA UK LTD·Filed 2023·Application pending·0 cites
- 1953US12344621B2CGRP antagonist compoundsNXERA PHARMA UK LTD·Filed 2020·Granted Jul 1, 2025·0 cites·31 claims
- 2052US12552799B2Triazolone compoundsNXERA PHARMA UK LTD·Filed 2021·Granted Feb 17, 2026·0 cites·7 claims
- 2151US12528815B25-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancerNXERA PHARMA UK LTD·Filed 2021·Granted Jan 20, 2026·0 cites·11 claims
- 2250US12441777B2GLP-1 receptor antagonistsNXERA PHARMA UK LTD·Filed 2019·Granted Oct 14, 2025·0 cites·17 claims
- 2345US12492174B2Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseasesNXERA PHARMA UK LTD·Filed 2025·Granted Dec 9, 2025·0 cites·29 claims
Join the waitlist — get patent alerts
Get an alert when NXERA PHARMA UK LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →